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To explore the clinical efficacy and safety of subcutaneous (SC) rozanolixizumab, an anti-
neonatal Fc receptor humanized monoclonal antibody, in patients with generalized myasthenia
gravis (gMG).
Methods
In this phase 2a, randomized, double-blind, placebo-controlled, 2-period, multicenter trial
(NCT03052751), patients were randomized (1:1) in period 1 (days 1–29) to 3 once-weekly
(Q1W) SC infusions of rozanolixizumab 7 mg/kg or placebo. In period 2 (days 29–43),
patients were re-randomized to either rozanolixizumab 7 mg/kg or 4 mg/kg (3 Q1W SC
infusions), followed by an observation period (days 44–99). Primary endpoint was change from
baseline to day 29 in Quantitative Myasthenia Gravis (QMG) score. Secondary endpoints were
change from baseline to day 29 in MG–Activities of Daily Living (MG-ADL) and MG-
Composite (MGC) scores and safety.
Results
Forty-three patients were randomized (rozanolixizumab 21, placebo 22 [period 1]). Least
squares (LS) mean change from baseline to day 29 for rozanolixizumab vs placebo was as
follows: QMG (LS mean −1.8 vs −1.2, difference −0.7, 95% upper confidence limit [UCL] 0.8;
p = 0.221; not statistically significant), MG-ADL (LS mean −1.8 vs −0.4, difference −1.4, 95%
UCL −0.4), and MGC (LS mean −3.1 vs −1.2, difference −1.8, 95% UCL 0.4) scores. Efficacy
measures continued to improve with rozanolixizumab 7 mg/kg in period 2. The most common
adverse event in period 1 was headache (rozanolixizumab 57%, placebo 14%).
Conclusion
Whereas change from baseline in QMG was not statistically significant, the data overall suggest
rozanolixizumab may provide clinical benefit in patients with gMG and was generally well
tolerated. Phase 3 evaluation is ongoing (NCT03971422).
Classification of Evidence
This study provides Class I evidence that for patients with gMG, rozanolixizumab is well-
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Acquired myasthenia gravis (MG) is an autoimmune disease
driven by the presence of pathogenic immunoglobulin G
(IgG) autoantibodies that impair synaptic transmission at the
neuromuscular junction.1
Therapeutic approaches for MG and other IgG-driven autoim-
mune diseases are evolving, with an increased interest in more
targeted approaches, such as reducing pathogenic IgG autoan-
tibodies by targeting the neonatal Fc receptor (FcRn).2 The
physiologic role of FcRn is to maintain IgG and albumin ho-
meostasis.3 When bound to FcRn, IgG is saved from lysosomal
degradation and is recycled into the circulation.3,4 Howard et al.2
reported reductions in pathogenic IgG autoantibodies and
clinical improvements in patients with MG following treatment
with an FcRn antagonist (efgartigimod). Limitations of current
treatments (e.g., IV immunoglobulin [IVIg] and plasma ex-
change [PLEX]) include an uncertain mode of action with IVIg
and removal of other plasma proteins besides IgG with
PLEX.3,5,6 Targeting FcRn may offer an alternative treatment
option for patients with MG vs current treatments, with im-
proved tolerability and a reduced treatment burden.
Rozanolixizumab, a subcutaneously (SC) infused monoclonal
antibody that specifically targets FcRn, prevents IgG recycling
by inhibiting the interaction of FcRn with IgG; lack of IgG
binding results in unbound IgG being eliminated via the
natural lysosomal degradation pathway.7 We have previously
shown dose-dependent reductions in IgG concentrations
following IV and SC infusions of rozanolixizumab in a first-in-
human trial in healthy volunteers.8
The study described here explored the dose and frequency of
rozanolixizumab SC infusion in patients with moderate to
severe generalized MG (gMG) and we report, for the first




This phase 2a randomized controlled trial sought to de-
termine the clinical efficacy, safety, tolerability, and pharma-
codynamic (PD) effect of rozanolixizumab in patients with
gMG. This study intended to provide Class I evidence that,
for patients with gMG, rozanolixizumab is well-tolerated and
improves Quantitative Myasthenia Gravis (QMG) score.
Trial Design and Patients
This multicenter, phase 2a, randomized, investigator- and
patient-blind, placebo-controlled, 2-period, treatment-
sequence trial, evaluating the clinical efficacy, safety, and tol-
erability of rozanolixizumab in patients with moderate to
severe gMG, was conducted at 17 sites.
Patients were eligible to participate if they were at least 18
years of age and had a documented diagnosis of gMG with
evidence of elevated autoantibodies (anti-acetylcholine re-
ceptor [AChR] or anti-muscle-specific kinase [MuSK]) prior
to screening. Eligibility required that, in the opinion of the
investigator, IVIg or PLEXmight be considered as a treatment
option. A QMG score of ≥11 at baseline and a serum total IgG
concentration of >6 g/L at screening were also required.
Patients were excluded if MG affected only the ocular mus-
cles, they were in myasthenic crisis at screening or showing
signs of imminent myasthenic crisis, or experiencing severe
weakness affecting oropharyngeal or respiratory muscles. In
addition, patients were excluded if they had previously re-
ceived rozanolixizumab treatment, had received another in-
vestigational medicinal product within 30 days of screening,
or had a known hypersensitivity to any component of roza-
nolixizumab, including L-proline. Patients with renal impair-
ment (serum creatinine ≥1.4 mg/dL [women], ≥1.5 mg/dL
[men]) or >2x upper limit of normal (ULN) for alanine
aminotransferase, aspartate aminotransferase, alkaline phos-
phatase, or > ULN total bilirubin were excluded from the trial.
Patients with a family history of primary immunodeficiency, a
clinically relevant active infection, a serious infection requiring
hospitalization within 6 weeks prior to first dose of rozano-
lixizumab, or those with clinically relevant ongoing infections
were excluded. Patients who were treated with rituximab 6
months prior to the baseline visit (or within 12 months if
B cells remained outside of normal range) were excluded.
Patients were excluded if they had received the immunosup-
pressants cyclophosphamide or pimecrolimus or vinca alka-
loids within 6 months, 4 weeks, and 12 weeks, respectively,
prior to the baseline visit; the biological agents abatacept,
belimumab, golimumab, natalizumab, ofatumumab, or veltu-
zumab within 6 months of the baseline visit; or trans-
membrane activator and calcium modulator and cyclophilin-
ligand interactor (TACI) Ig within 10 months of the baseline
visit; received other treatments such as IVIg or SC immu-
noglobulins (3 months prior to baseline), IPP-201101 (3
months prior to baseline), PLEX, or immunoabsorption (6
Glossary
AChR = acetylcholine receptor; AE = adverse event; FAS = full analysis set; FcRn = neonatal Fc receptor; gMG = generalized
myasthenia gravis; IgG = immunoglobulin G; IVIg = IV immunoglobulin; LS = least squares; MG = myasthenia gravis; MG-
ADL = Myasthenia Gravis–Activities of Daily Living;MGC = Myasthenia Gravis–Composite;MuSK = muscle-specific kinase;
PD = pharmacodynamic; PD-PPS = pharmacodynamic per protocol analysis set; PLEX = plasma exchange; Q1W = once-
weekly; QMG = Quantitative Myasthenia Gravis; SAE = serious adverse event; SC = subcutaneously; SS = safety set; UCL =
upper confidence limit; ULN = upper limit of normal.
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weeks prior to baseline visit); or if they had been thymec-
tomized in the past 6 months or had a history of a thymoma
requiring chemotherapy or radiotherapy.
Standard Protocol Approvals, Registrations,
and Patient Consents
The trial (ClinicalTrials.gov Identifier: NCT03052751) was
performed in accordance with the principles of the Declara-
tion of Helsinki and the International Conference on Har-
monisation Guidance for Good Clinical Practice. The study
protocol (appendix), amendments, and patient-informed
consent were reviewed by national, regional, or independent
ethics committees or institutional review boards. Written in-
formed consent was obtained from all patients.
Procedures
Adults with moderate to severe gMG were randomized 1:1 in
dosing period 1 (days 1–29) to receive 3 once-weekly (Q1W)
SC infusions of rozanolixizumab 7 mg/kg or placebo; treat-
ment was administered on days 1, 8, and 15. SC infusions of
rozanolixizumab were administered into the abdominal wall,
using an infusion pump, at an infusion speed of 20 mL/h over
30 minutes. A treatment-free period of 2 weeks occurred
between the last dose in period 1 (day 15) and initiation of
period 2 (day 29). Patients were stratified based on the
treatment received in period 1 and re-randomized in period
2 (days 29–43); the placebo group and the rozanolixizumab
7 mg/kg group were each re-randomized to 3 Q1W SC in-
fusions of either rozanolixizumab 7 mg/kg or 4 mg/kg in a 1:1
manner. For dosing period 2, treatment was administered on
days 29, 36, and 43; days 44–99 constituted an observation
period. The dosing period time points were based on PD
observations from the first-in-human study8 and subsequent
modeling.
The multiple arms of period 2 aimed to determine the sus-
tainability of any clinical effects and the safety of longer treat-
ment with 7 mg/kg rozanolixizumab (7 mg/kg / 7 mg/kg);
assess whether the 4 mg/kg dose was sufficient to maintain
clinical effects (rozanolixizumab 7 mg/kg / 4 mg/kg); and
assess whether the 4 mg/kg dose was sufficient to elicit a
beneficial effect (placebo/rozanolixizumab 4 mg/kg).
Interactive response technology, provided by an external
vendor, was used to anonymize (5-digit identifier) and ran-
domize patients to treatment groups. Upon re-randomization
in dosing period 2, a second unique randomization number
was also assigned.
To ensure trial blinding, injections were prepared at the in-
vestigational sites by unblinded, designated study-site phar-
macists. All other trial personnel remained blinded and did
not have access to medication-related information.
Outcomes
The primary objective was to evaluate the clinical efficacy to
day 29 of rozanolixizumab as a chronic/intermittent
treatment in patients with moderate to severe gMG. Sec-
ondary objectives were to evaluate the safety, tolerability, and
PD effects of rozanolixizumab. An additional exploratory
objective aimed to assess the effect of rozanolixizumab on
MG-specific serum autoantibodies (anti-AChR and anti-
MuSK).
Change in QMG score from baseline to day 29 (period 1) was
the primary endpoint. Secondary endpoints included change
in MG–activities of daily living (MG-ADL) and MG–
composite (MGC) scores from baseline to day 29 (period 1).
Other variables, all assessed from baseline over the entire trial
duration (periods 1 and 2), were changes in QMG,MG-ADL,
and MGC scores; assessment of QMG, MG-ADL, and MGC
score responder rate (≥3.0-point improvement); incidence of
adverse events (AEs; categorized as preferred terms, accord-
ing to the Medical Dictionary for Regulatory Activities
v.21.0); change in total serum IgG concentration; and change
in MG-specific autoantibody concentrations.
Statistical Methods
The trial aimed to demonstrate that the reduction in QMG
score between baseline and day 29 would be greater in the
rozanolixizumab 7 mg/kg group compared with placebo. The
sample size calculation used a one-sided 5% significance level,
an estimate of the SD for change in QMG of 3.4, and an
anticipated treatment effect of 3.4 (as observed previously in
patients with severe disease).9 Based on these assumptions, a
sample size of 40 would be required to detect a statistically
significant treatment difference between rozanolixizumab and
placebo in mean change from baseline in QMG at day 29 with
a power >90%.
All randomized patients who received ≥1 dose of rozanolix-
izumab were included in the safety set (SS); efficacy analyses
included all randomized patients who had received ≥1 dose of
rozanolixizumab and had a baseline and ≥1 postbaseline
QMG measurement during dosing period 1 (full analysis set;
FAS). A subset of the FAS, the pharmacodynamic per pro-
tocol set (PD-PPS), was used for analysis of serum total IgG
concentrations; these patients had no important protocol
deviation affecting serum concentrations.
The primary analysis of mean change from baseline in QMG
was based on a mixed-model repeated-measures analysis in-
cluding terms for treatment group, baseline QMG score, and
the interaction between treatment group and week. The
model defined patient as a random effect and utilized an un-
structured covariance pattern. We provide a 1-sided p value
and upper confidence limits (UCLs).
Three interim analyses were performed, none of which had an
impact on the α level. The first assessed futility (based on
QMG, MG-ADL, and MGC scores) and took place once 20
patients had reached day 29; evidence of futility would have
resulted in halting or amending the trial. The second interim
analysis, conducted by the data monitoring committee,
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considered the safety of rozanolixizumab and took place once
20 patients had reached day 57. The third interim analysis was
performed once all patients had reached day 29, when the data
for the primary endpoint (mean change from baseline to day
29 in QMG score) and secondary efficacy variables (mean
change from baseline to day 29 in MG-ADL and MGC
scores) were generated.
Data Availability
Underlying data from this article may be requested by qualified
researchers 6 months after product approval in the United States
or Europe, or global development is discontinued; and 18
months after trial completion. Investigators may request access to
anonymized individual patient data and redacted trial documents,
which may include raw datasets, analysis-ready datasets, trial
protocol, blank case report form, annotated case report form,
statistical analysis plan, dataset specifications, and clinical trial
report. Prior to use of the data, proposals need to be approved by
an independent review panel at clinicalstudydatarequest.com and
a signed data sharing agreement will need to be executed. All
documents are available in English only, for a prespecified time,
typically 12 months, on a password-protected portal.
Results
The first patient was enrolled on May 15, 2017, and the last
patient completed on August 6, 2018. Sixty-nine patients were
screened across 21 sites, of whom 43 (from 17 sites) initiated
rozanolixizumab treatment (FAS and SS; figure 1).
Patient demographics (table 1) were broadly similar between
treatment groups at baseline. The combination of the repor-
ted baseline MG-ADL and MGC scores, as well as the
protocol-defined entry criteria of QMG score ≥11 and eligi-
bility for IVIg/PLEX, indicated a population with moderate to
severe MG.
Improvements from baseline to day 29 in QMG score for
rozanolixizumab compared with placebo were not statisti-
cally significant (least squares [LS] mean: −1.8 vs −1.2;
difference: −0.7; 95% UCL: 0.8; p = 0.221; figure 2A).
Improved day-to-day function, as measured by change from
baseline to day 29 in MG-ADL, was observed following
treatment with rozanolixizumab compared with placebo
(LS mean: −1.8 vs −0.4; difference: −1.4; 95% UCL: −0.4;
figure 2B). MGC score also showed changes from baseline
to day 29 with rozanolixizumab compared with placebo (LS
mean: −3.1 vs −1.2; difference: −1.8; 95% UCL 0.4; figure
2C). Following treatment with rozanolixizumab, LS mean
reductions from baseline in QMG andMGC scores reached
their nadir 1 week after the final period 1 infusion (day 22;
−2.4 and −3.3, respectively) with increases towards base-
line values in scores observed between day 22 and day 29,
before initiation of period 2.
Figure 1 CONSORT (Consolidated Standards of Reporting Trials) Diagram
aDid not meet inclusion criteria. bDiscontinued treatment due to a severe adverse event (AE) (headache) but continued in the observation period.
e856 Neurology | Volume 96, Number 6 | February 9, 2021 Neurology.org/N
Table 1 Baseline Characteristics and Demographics of the Full Analysis Set











Rozanolixizumab 7 mg/kg/rozanolixizumab 7 mg/
kg (n = 10)
Rozanolixizumab 7 mg/kg/rozanolixizumab 4 mg/
kg (n = 10)
Age, y 53.3
(15.7)
50.5 (14.7) 52.1 (14.4) 54.5 (17.5) 47.9 (16.0) 52.0 (14.2) 51.9 (15.1)
Sex, male 8 (36) 8 (38) 5 (45) 3 (27) 4 (40) 4 (40) 16 (37)
Weight, kg 86.1
(21.4)
88.2 (20.0) 85.9 (16.4) 86.3 (26.3) 85.3 (24.3) 87.9 (13.1) 87.1 (20.5)
Autoantibody class
AChR 21 (95) 19 (90) 11 (100) 10 (91) 9 (90) 9 (90) 40 (93)
MuSK 0 1 (5) 0 0 1 (10) 0 1 (2)
Ethnicity
Hispanic or Latino 1 (5) 1 (5) 0 1 (9) 0 1 (10) 2 (5)
Not Hispanic or Latino 21 (96) 20 (95) 11 (100) 10 (91) 10 (100) 9 (90) 41 (95)
Geographic region, United
States
3 (14) 6 (29) 2 (18) 1 (9) 3 (30) 2 (20) 9 (21)
MGFAdisease class at baselinea
Class II 9 (41) 10 (48) 4 (36) 5 (46) 7 (70) 2 (20) 19 (44)
Class III 12 (55) 9 (43) 7 (64) 5 (46) 3 (30) 6 (60) 21 (49)
Class IV 1 (5) 2 (10) 0 1 (9) 0 2 (20) 3 (7)
QMG score at baseline 15.4 (3.6) 16.0 (4.2) 15.6 (3.5) 15.2 (4.0) 15.0 (2.4) 16.9 (5.7) N/A
MGC score at baseline 13.9 (6.0) 17.5 (6.0) 13.3 (4.5) 14.5 (7.4) 18.0 (5.1) 16.9 (7.4) N/A
MG-ADL score at baseline 6.1 (2.6) 8.2 (3.3) 6.3 (2.7) 5.9 (2.7) 7.5 (3.4) 8.7 (3.4) N/A
MG treatments at baseline
Corticosteroids (for systemic
use)
11 (50) 9 (43) 6 (55) 5 (46) 3 (30) 5 (50) 20 (47)
Immunosuppressants 11 (50) 10 (48) 5 (46) 6 (55) 4 (40) 5 (50) 21 (49)
Parasympathomimetics 19 (86) 20 (95) 10 (91) 9 (82) 10 (100) 9 (90) 39 (91)
Thymectomy prior to
baseline (yes)
10 (46) 11 (52) 4 (36) 6 (55) 5 (50) 6 (60) 21 (49)
Abbreviations: AChR = acetylcholine receptor; MG = myasthenia gravis; MG-ADL = Myasthenia Gravis–Activities of Daily Living; MGC = Myasthenia Gravis–Composite; MGFA = Myasthenia Gravis Foundation of America;
MuSK = muscle-specific kinase; QMG = Quantitative Myasthenia Gravis.
Values are mean (SD) or n (%). Data for dosing period 2 show analysis of baseline data according to period 2 re-randomization.




















Day 29 responder rates (≥3.0-point improvement from
baseline) were higher in patients receiving rozanolixizumab 7
mg/kg vs placebo for QMG (38% vs 23%), MG-ADL (48% vs
14%), and MGC (48% vs 27%) scores (figure 3, A–C).
Compared with day 29, greater responder rates with roza-
nolixizumab were observed on day 22 (1 week after the final
dose), when 52% of patients receiving rozanolixizumab 7 mg/
kg achieved a clinically meaningful (3.0-point) improvement
in QMG score and 55% of patients receiving rozanolixizumab
7 mg/kg achieved a clinically meaningful (3.0-point) im-
provement in MGC score. MG-ADL was not assessed at day
22, hence responder rates could not be determined.
Continuation of rozanolixizumab 7 mg/kg treatment in pe-
riod 2 resulted in further improvements in QMG, MG-ADL,
and MGC scores. QMG and MG-ADL scores reached a
maximum reduction 21 days after re-initiation of rozanolix-
izumab (7 mg/kg) treatment (day 50; figure 4, A and B).
MGC score nadir was achieved 14 days after re-initiation of
rozanolixizumab (7 mg/kg) treatment (day 43; figure 4C).
Following cessation of period 2 treatment, QMG, MG-ADL,
and MGC scores all increased towards the baseline values, to
the end of the observation period (day 99; figure 4, A–C).
Patients re-randomized from rozanolixizumab 7 mg/kg to
rozanolixizumab 4 mg/kg in period 2 maintained modest
reductions for QMG, MG-ADL, and MGC scores from day
29 (figure 4, A–C). Nadir was observed for all 3 measures 21
days after the first rozanolixizumab (4 mg/kg) dose was ad-
ministered (day 50). The reduction in QMG score was
maintained to day 78 (figure 4A).
Both the placebo/rozanolixizumab 4 mg/kg and placebo/
rozanolixizumab 7 mg/kg groups showed improvements in
QMG, MG-ADL, and MGC scores (figure 4, A–C), which
appeared dose-related.
Exploratory analyses (PD-PPS) showed a reduction in total
serum IgG concentration for all dose groups after adminis-
tration of rozanolixizumab (figure 5A). In period 1, treatment
with rozanolixizumab resulted in a rapid reduction of IgG
concentrations vs placebo (52% vs 4%, respectively; day 29);
the nadir in IgG concentration following treatment with
rozanolixizumab occurred by day 22 (61%). Following period
2 re-randomization, continuation of rozanolixizumab 7mg/kg
further reduced IgG concentration (maximum decrease 68%
by day 50). The rozanolixizumab 7 mg/kg/4 mg/kg
dose group maintained a reduction in IgG concentration
with the nadir observed on day 50 (59%). The placebo/
rozanolixizumab 7 mg/kg and placebo/rozanolixizumab
4 mg/kg dose groups both showed dose-related reductions
in IgG concentrations.
Reductions in serum anti-AChR autoantibody titres (FAS)
were observed following treatment with rozanolixizumab
(figure 5B). In period 1, mean reductions were greater fol-
lowing rozanolixizumab treatment compared with placebo
(44% reduction from baseline vs 6% increase from baseline,
respectively), and showed a slight delay when compared with
reductions in total IgG. The period 2 profile showed a similar
Figure 2 Change in Measures of Clinical Effect from Base-
line to Day 29 (Period 1)
Change frombaseline to day 29 in (A) QuantitativeMyasthenia Gravis (QMG)
score, (B) Myasthenia Gravis–Activities of Daily Living (MG-ADL) score, and
(C) Myasthenia Gravis–Composite (MGC) score. Data are least squares (LS)
mean change frombaseline of the full analysis set; error bars show SEM. CI =
confidence interval; SEM = standard error of the mean.
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pattern to that observed with the reduction in IgG concen-
tration; rozanolixizumab 7 mg/kg / 7 mg/kg continued to
reduce IgG to a nadir of 68% (day 36) and the reduction was
maintained to day 50. Rozanolixizumab 7 mg/kg / 4 mg/kg
maintained the reduction observed in period 1. The placebo/
rozanolixizumab 7 mg/kg and placebo/rozanolixizumab
4 mg/kg dose groups showed comparable reductions in
anti-AChR autoantibody concentrations in period 2. Anti-
MuSK autoantibody concentrations are not described due to
low patient numbers (n = 1).
During dosing period 1, 16/21 (76%) patients receiving
rozanolixizumab and 16/22 (73%) patients receiving pla-
cebo reported at least 1 AE (table 2). None of the 21
patients receiving rozanolixizumab 7 mg/kg and 2/22 (9%)
patients receiving placebo reported serious AEs (SAEs)
during period 1. By the end of the observation period (day
99), 36/43 (84%) patients reported 1 or more AE, and
5/43 (12%) reported 1 or more SAE. Overall, 4
rozanolixizumab-treated patients withdrew from the trial, 1
due to MG crisis (SAE) and 3 due to headache (2 due to the
prespecified protocol withdrawal criteria of severe head-
ache [1 SAE]; 1 moderate headache). No deaths occurred
during the trial.
Most commonly reported AEs during period 1 (≥5% of all
patients, SS) are summarized in table 2. In period 1, higher
frequency of headaches was reported in patients receiving
7 mg/kg (57%) compared with placebo (14%). Most
headaches were mild to moderate. All instances of head-
ache resolved with standard therapies and without
sequelae.
Figure 3 Responder Rate Analysis (Full Analysis Set) at Day 29 for Measures of Clinical Effect
Day 29 responder rates (≥3.0-point improvement from
baseline) for (A) Quantitative Myasthenia Gravis (QMG) score,
(B) Myasthenia Gravis–Activities of Daily Living (MG-ADL)
score, and (C) Myasthenia Gravis–Composite (MGC) score.
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Period 1 AEs deemed by the investigator to be related to
treatment were reported in 10/21 patients receiving rozano-
lixizumab 7 mg/kg and 5/22 patients receiving placebo (table
2). Headache was the most common treatment-related AE
(8/21 [38%] patients receiving rozanolixizumab 7 mg/kg and
2/22 [9%] patients receiving placebo). Infusion site reactions
occurred in 1 patient in each of the following groups: placebo
(4.5%, period 1), placebo/rozanolixizumab 4 mg/kg (9.1%,
period 2), rozanolixizumab 7 mg/kg/7 mg/kg (10%, pe-
riod 2).
The incidence of infections between rozanolixizumab and
placebo groups was similar (table 2). During period 1, the
most common infections were nasopharyngitis and upper
respiratory tract infection. During period 2, 1 patient in the
rozanolixizumab 7 mg/kg/7 mg/kg group and 2 patients in
each of the other arms reported infections and infestations.
No serious or opportunistic infections were reported during
the trial.
Discussion
Rozanolixizumab is an SC-infused FcRn inhibitor in de-
velopment for the treatment of IgG autoantibody-mediated
diseases, including MG. This is the first trial to assess the
therapeutic potential of rozanolixizumab in patients with gMG
and our results across efficacy measures, together with data
reported by Howard et al.,2 offer important insights into the
viability of inhibition of FcRn as a therapeutic approach in
gMG. Although the primary endpoint (change from baseline in
QMG score to day 29) was not statistically significant, overall,
considering a range of prespecified clinical efficacy measures
(QMG, MG-ADL, and MGC), the data suggest rozanolix-
izumab has potential to provide clinical benefit in patients with
moderate to severe gMG. Furthermore, rozanolixizumab was
associated with reductions in anti-AChR autoantibodies and
was well-tolerated across 2 dose levels with no new safety
findings compared to previously reported data.8,10 The com-
bination of favorable clinical and proof-of-concept PD effects
warrants further evaluation of rozanolixizumab in larger, ade-
quately powered phase 3 trials.
This trial has provided important insights into the appropriate
dose and optimal timing of rozanolixizumab infusion for
measurement of efficacy; these insights have informed the
design of the ongoing phase 3 trial. Of the 2 rozanolixizumab
doses studied, 7 mg/kg yielded the greatest reductions from
baseline for all efficacy and PD measures (e.g., the outcomes
of the rozanolixizumab 7 mg/kg / 7 mg/kg dose group),
making it a proposed dose for future studies. Analyses of
efficacy and PD variables showed weekly infusions to be the
optimal treatment regimen, since better responses were
observed 1 week after last dose (day 22) rather than at the
Figure 4 Change From Baseline in Measures of Clinical Effect (Full Analysis Set) According to Periods 1 and 2
Change frombaseline for (A) QuantitativeMyasthenia Gravis (QMG) score, (B) Myasthenia Gravis–Activities of Daily Living (MG-ADL) score, and (C)Myasthenia
Gravis–Composite (MGC) score. SEM = standard error of the mean.
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primary endpoint assessment (day 29, 2 weeks after last dose).
Extension of the initial 3-week dosing period (period 1) with
additional doses of rozanolixizumab in period 2 led to further
reductions in QMG, MG-ADL, and MGC scores compared
with period 1, suggesting that a dosing period of 6 weeks
(Q1W) might yield a better clinical response. This is also
consistent with data showing that the maximum response to
PLEX generally occurs 6 weeks after treatment.11
Across studies, PD assessment of rozanolixizumab has con-
sistently demonstrated rapid and dose-dependent reductions
in serum IgG concentration, with maximum mean decreases
of 43%–51% observed following rozanolixizumab SC 7 mg/
kg.8,10 In the current trial, a maximummean decrease in serum
IgG concentration of 68% was observed for the rozanolix-
izumab 7 mg/kg / 7 mg/kg dose group. This proof of concept
supports preclinical findings and adds clinical evidence that
rozanolixizumab reduces circulating pathogenic IgG by
disrupting the natural IgG recycling mechanism.7 Other
treatments, such as PLEX, have demonstrated IgG reductions
of up to 73%.11
Anti-AChR autoantibody reduction following rozanolixizumab
treatment was similar to levels observed after PLEX11 (68% vs
71%, respectively). Despite treatment with rozanolixizumab
resulting in up to 68% reduction in anti-AChR autoantibodies,
no consistent correlation with clinical effects was observed.
These data are consistent with previous studies reporting no
associations between anti-AChR antibodies and clinical im-
provements in MG.12–14
In addition to issues around timing of efficacy assessments, it
should also be considered whether there is a need for more
robustMG endpoints. It is known that the clinical significance of
a change in QMG score can be affected by baseline disease
severity and that subtleties exist when assessing treatment re-
sponse with QMG (percentage change or point change from
baseline).15,16 Furthermore, reported changes in QMG score
vary widely between clinical trials, even those using consistent
treatment regimens.9,17,18 Consideration of these points in
conjunction with the findings of this study suggests that further
investigation to explore the sensitivity of clinical scales when
assessing treatment response in MG studies could be beneficial.
Figure 5Mean Percent Change From Baseline in Serum Immunoglobulin G (IgG) (Pharmacodynamic per Protocol Analysis
Set) and Anti–acetylcholine Receptor (AChR) (Full Analysis Set [FAS]) Following Rozanolixizumab Treatment
(A) Serum IgG concentration. (B) Serum AChR autoantibody concentration. Data are from FAS group members who were AChR-positive at baseline; up to 40
patients in period 1 and up to 39 patients in period 2 are included in the analysis. For both graphs, data are presented asmean percent change frombaseline,
error bars show standard error of the mean (SEM).
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Table 2 Adverse Events (AEs), n (%)a







7 mg/kgb (n = 21)
Placebo/
rozanolixizumab
7 mg/kg (n = 11)
Placebo/rozanolixizumab
4 mg/kg (n = 11)
Rozanolixizumab 7 mg/kg/
rozanolixizumab 7 mg/kgb (n = 10)
Rozanolixizumab 7 mg/kg/
rozanolixizumab 4 mg/kgb (n = 10)
Any AE 16 (73) 16 (76) 7 (64) 9 (82) 9 (90) 9 (90) 36 (84)
Serious AE 2 (9) 0 3 (27) 1 (9) 1 (10) 0 5 (12)
Discontinuation due
to AEd
0 1 (5) 2 (18) 0 1 (10) 0 4 (9)
Treatment-related AE 5 (23) 10 (48) 3 (27) 4 (36) 7 (70) 7 (70) 24 (56)
Severe AE 3 (14) 3 (14) 4 (36) 1 (9) 1 (10) 0 9 (21)
AE of intereste 1 (5) 2 (10) 2 (18) 1 (9) 0 1 (10) 6 (14)
Diarrhea/anal
incontinence
1 (5) 1 (5) 0 1 (9) 0 1 (10) 3 (7)
Headache 0 1 (5) 2 (18) 0 0 0 3 (7)
Death 0 0 0 0 0 0 0
Most commonAE (≥5%
patients)
Diarrhea 2 (9) 3 (14) 1 (9) 4 (36) 1 (10) 2 (20) 11 (26)
Nausea 1 (5) 2 (10) 0 0 1 (10) 2 (20) 5 (12)
Vomiting 1 (5) 1 (5) 0 0 2 (20) 0 3 (7)
Fatigue 3 (14) 1 (5) 1 (9) 1 (9) 0 0 3 (7)
Nasopharyngitis 3 (14) 1 (5) 0 0 1 (10) 0 1 (2)
Upper respiratory
tract infection
1 (5) 2 (10) 1 (9) 1 (9) 0 0 4 (9)
Muscle spasms 1 (5) 1 (5) 0 0 0 1 (10) 2 (5)
Muscular weakness 0 1 (5) 2 (18) 0 0 1 (10) 3 (7)
Headache 3 (14) 12 (57) 4 (36) 2 (18) 4 (40) 4 (40) 21 (49)
Dizziness 3 (14) 1 (5) 0 0 2 (20) 1 (10) 4 (9)























Observations from this trial warrant further investigation
as part of a larger phase 3 trial. For example, when the
group of patients receiving 7 mg/kg rozanolixizumab in
period 1 was analyzed by treatment allocation in period 2,
clinical response appeared greater during period 1 in the
subgroup that initially received 7 mg/kg and continued on
7 mg/kg compared with patients who initially received
7 mg/kg and continued on 4 mg/kg in period 2. These
differences could be accounted for by an imbalance in
baseline characteristics between the 2 groups. For example,
the group that received 7 mg/kg throughout the trial had a
lower mean age, milder Myasthenia Gravis Foundation of
America disease classification scores, and lower QMG
scores at baseline compared with patients who switched
from 7 mg/kg to 4 mg/kg in period 2. Understanding the
effect of patient age and disease severity on the clinical
effects of rozanolixizumab in MG will be important con-
siderations in future trials.
The safety results reported in this trial are consistent with
previous studies of rozanolixizumab. Assessment of safety in 2
prior studies (a first-in-human, placebo-controlled, single-dose,
dose-escalating trial [NCT02220153] and a phase 2 trial in-
volving patients with primary immune thrombocytopenia
[NCT02718716]) showed an acceptable safety profile after
7 mg/kg SC infusions of rozanolixizumab.8,10 Both studies
reported headache as the most common AE, which is consis-
tent with the current trial. The reason headaches appear to be
associated with FcRn inhibitors remains unclear, but will con-
tinue to be explored as more data become available.
IVIg and PLEX are among the current treatment options for
patients with worsening gMG despite their uncertain modes
of action3,5,6 and limited evidence from randomized clinical
trials.19–21 While effective at relieving the clinical symptoms
for patients with MG, both IVIg and PLEX are associated
with a high treatment burden and can be associated with
considerable AEs that often require comedications.22,23
Both treatments also require specialist IV preparations and
long administration times, resulting in a significant burden
on the health care system.22–24 Exploratory results using
novel anti-FcRn therapies, including rozanolixizumab
reported here, and the recently reported phase 2 study of
efgartigimod,2 suggest clinically meaningful improvements
in patients with gMG. These therapeutic approaches have
the potential to reduce treatment burden for a range of
patients living with MG, as well as other IgG-driven auto-
immune conditions.
Limitations of this trial are that a small number of patients were
enrolled, and the testing of the primary efficacy hypothesis was
single-sided; therefore, the level of interpretation/extrapolation
that can be applied to these results may be limited. Data on the
duration of MG in this trial population were not collected;
consequently, no assessment of whetherMGduration influences
rozanolixizumab efficacy could be performed. As noted, the
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efficacy 2 weeks after the final dose may have been insufficient,
and a longer treatment period may be required to exert efficacy
in the overall population.
In conclusion, the primary endpoint did not show signifi-
cant improvement in QMG score (from baseline to day
29), but when all prespecified efficacy measures (QMG,
MG-ADL, and MGC) are considered, the data overall
suggest rozanolixizumab, a humanized monoclonal anti-
body specifically targeting FcRn, may provide clinical
benefit for patients with moderate to severe gMG. Proof-of-
concept PD effects were also seen with rozanolixizumab.
These data support further evaluation in the ongoing phase
3 study (NCT03971422) to assess the efficacy of rozano-
lixizumab in the treatment of MG, with potential to offer a
targeted approach to treatment.
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